Skip to main content
Journal of Experimental & Clinical Cancer Research : CR logoLink to Journal of Experimental & Clinical Cancer Research : CR
. 2022 Jan 27;41:40. doi: 10.1186/s13046-022-02247-y

Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Ilaria Romito 1,#, Manuela Porru 2,#, Maria Rita Braghini 1,#, Luca Pompili 2, Nadia Panera 1, Annalisa Crudele 1, Daniela Gnani 3, Cristiano De Stefanis 4, Marco Scarsella 4, Silvia Pomella 5, Stefano Levi Mortera 6, Emmanuel de Billy 5, Adrian Libenzio Conti 4, Valeria Marzano 6, Lorenza Putignani 6,7, Manlio Vinciguerra 8,9, Clara Balsano 10,11, Anna Pastore 12, Rossella Rota 5, Marco Tartaglia 13, Carlo Leonetti 2, Anna Alisi 1,
PMCID: PMC8793270  PMID: 35086550

Correction to: J Exp Clin Cancer Res 40, 364 (2021).

https://doi.org/10.1186/s13046-021-02154-8

Following publication of the original article [1], the authors identified errors Figs. 3, 4, 5 and 6 specifically:

Fig. 3.

Fig. 3

Evaluation of pTyr397FAK, cell cycle, apoptosis and TS morphology in HCC cells after TAE226 > SOR treatment. A Scheme of the experimental design. Representative immunoblot and quantitative analysis of pTyr397FAK expression after 48 h from treatment with the different drugs, in HepG2 (B) and Huh7 cells (C). αTubulin served as loading control. Values are the mean arbitrary units ± SD of at least three independent experiments. Data were analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT. D Percentage of HCC cells in G0/G1, S and G2/M phase of the cell cycle by PI staining and flow cytometry analysis. Data are expressed as mean ± SD of at least three independent experiments and analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT. E Percentage of HCC cells dead or in early and late apoptosis measured by Annexin V staining and flow cytometry. Data are expressed as mean ± SD of at least three independent experiments and analysed by 2-tailed Student’s t test. **p < 0.01; ***p < 0.001 vs. NT. F Representative brightfield and fluorescent images (Hoechst and PI) of multicellular TS from HepG2 and Huh7 cells NT and after treatments

Fig. 4.

Fig. 4

Effect of TAE226 > SOR on HCC growth in mouse xenograft model. A Scheme of the experimental design. Imaging analysis was performed at different times (I). B Quantitative analysis and representative pictures of in vivo bioluminescence imaging analysed before administration of compounds (day 0) and during treatments at days 14, 21, 28 or 35. Luminescent signals are expressed as mean ± SD of total flux of photons/sec/cm2/steradian (p/s/cm2/sr). Data were analysed by ANOVA test. (**p < 0.01; n = 6). Representative images of immunofluorescence for PCNA (in red) (C) and pTyr397FAK (in green) (D) in mouse xenograft models after treatments. The nuclei are revealed by specific DAPI staining, displayed in blue. 40X Magnification

Fig. 5.

Fig. 5

Cancer associated genes upon FAK inhibition. A Heatmap representation of the expression of up-regulated (A) and down-regulated (B) cancer-related genes in HepG2 and Huh7 cells in TAE226 > SOR compared to NT cells. C Venn diagrams showing the overlapping of up-regulated (upper circles) and down-regulated (lower circles) genes in HepG2 and Huh7 cells treated with TAE226 > SOR compared to NT cells. D Bar plots of the 10 most abundant pathways for commonly up-regulated (upper plot) or down-regulated (lower plot) genes in both HCC cells after treatment with TAE226 > SOR

Fig. 6.

Fig. 6

Effect of TAE226 > SOR on H3K27me3. A H3K27me3 levels measured by AlphaLISA assay and represented as fold change in HepG2 and Huh7 cells treated vs. NT. Data were analysed by 2-tailed Student’s t test. **p < 0.01; ***p < 0.001 vs. NT. Representative immunoblot (B) and quantitative analysis (C) of EZH2 expression after treatments, in HepG2 and Huh7 cells. αTubulin served as loading control. Values are the mean of arbitrary units ± SD of at least three independent experiments. Data were analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT

Figure 3d - Percentage of HCC cells in G0/G1, S and G2/M phase of the cell cycle by PI staining and flow cytometry analysis. Data are expressed as mean ± SD of at least three independent experiments and analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT

Figure 4b - Quantitative analysis and representative pictures of in vivo bioluminescence imaging analysed before administration of compounds (day 0) and during treatments at days 14, 21, 28 or 35. Luminescent signals are expressed as mean ± SD of total flux of photons/sec/cm2/steradian (p/s/cm2/sr). Data were analysed by ANOVA test. (**p < 0.01 n = 6). Representative images of immunofluorescence for PCNA (in red)

Figure 5a, b, c - Heatmap representation of the expression of up-regulated; cancer-related genes in HepG2 and Huh7 cells in TAE226 > SOR compared to NT cells; Venn diagrams showing the overlapping of up-regulated (upper circles) and down-regulated (lower circles) genes in HepG2 and Huh7 cells treated with TAE226 > SOR compared to NT cells.

Figure 6c - EZH2 expression after treatments, in HepG2 and Huh7 cells. αTubulin served as loading control. Values are the mean of arbitrary units ± SD of at least three independent experiments. Data were analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT

In addition, the revised Supplementary materials also need to be corrected specifically, Additional files 6, 7 and 8.

The authors provided the Journal with the original data files. The corrected figures are given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.

Supplementary Information

Additional file 6. (125.2KB, docx)
Additional file 7. (133.4KB, docx)
Additional file 8. (278.7KB, docx)

Footnotes

Ilaria Romito, Manuela Porru and Maria Rita Braghini co-first authors.

Reference

  • 1.Romito I, Porru M, Braghini MR, et al. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res. 2021;40:364. doi: 10.1186/s13046-021-02154-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 6. (125.2KB, docx)
Additional file 7. (133.4KB, docx)
Additional file 8. (278.7KB, docx)

Articles from Journal of Experimental & Clinical Cancer Research : CR are provided here courtesy of BMC

RESOURCES